Pharmanet Names Dr. George Scott Vice President of Bioanalytical Services
News Jul 22, 2011
PharmaNet Development Group, Inc., has announced that it has appointed George Scott, PhD, as Vice President, Bioanalytical Services.
In this role, Dr. Scott will provide leadership for PharmaNet's GLP-compliant bioanalytical laboratories in the United States and Canada.
In addition, he will build upon PharmaNet's bioanalytical method development, validation and sample analysis services across the continuum of drug development and lead PharmaNet's geographical and service expansion strategies in bioanalysis.
"Dr. Scott has a very impressive scientific and operational experience base in bioanalysis," commented Riaz Bandali, President, Early Stage Development. "He has extensive knowledge of our clients' needs and is highly regarded in the industry for his scientific expertise and his business acumen."
Prior to joining PharmaNet, Dr. Scott served as Director of Pharmacokinetics and Drug Metabolism at Amgen, a world leader in biotechnology. He was responsible for overseeing the immunochemistry and small molecule bioanalytical capabilities.
He was also integrally involved in the Amgen Leadership Committee that managed strategic outsourcing decisions for small molecule and large molecule programs to global bioanalytical service providers.
Prior to Amgen, Dr. Scott was responsible for establishing and growing the global ligand binding services at another CRO.
Dr. Scott holds a Bachelors of Science in Neuroscience from Edinburgh University and was awarded a PhD from the University of Nottingham for studies in neuropharmacology.
After four years in post-doctoral positions at Dalhousie University and the University of Montreal, he served for two years as an Assistant Professor in the faculty of Dentistry at McGill University.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE